2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse eventsEvaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2023
Wireless technologies, non-ionizing electromagnetic fields and children: Identifying and reducing health risks
Davis D, Birnbaum L, Ben-Ishai P, Taylor H, Sears M, Butler T, Scarato T. Wireless technologies, non-ionizing electromagnetic fields and children: Identifying and reducing health risks. Current Problems In Pediatric And Adolescent Health Care 2023, 53: 101374. PMID: 36935315, DOI: 10.1016/j.cppeds.2023.101374.Peer-Reviewed Original Research
2021
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemicMiscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads
Mor A, Gardezi M, Jubanyik K, Simsek B, Seifer DB, Patrizio P, Esencan E, Imamoglu G, Zhang M, Nichols-Burns SM, Taylor HS. Miscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads. Fertility And Sterility 2021, 116: 462-469. PMID: 33461753, DOI: 10.1016/j.fertnstert.2020.10.006.Peer-Reviewed Original ResearchConceptsExtrauterine pregnancyVaginal bloodAlpha-fetoproteinOngoing pregnancyAFP levelsSanitary padsHigh alpha-fetoprotein levelsOngoing pregnancy groupProspective cohort studyAlpha-fetoprotein levelsAcademic medical centerPregnancy groupCohort studyMiscarriage casesFirst trimesterOffice visitsMedical CenterMAIN OUTCOMEPregnancyMedian levelsMiscarriageBloodAnxiety levelsAFPCharacteristic analysis
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherenceResponsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility And Sterility 2020, 114: 44-55. PMID: 32505383, DOI: 10.1016/j.fertnstert.2020.02.114.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painBone mineral densityNon-menstrual pelvic painPelvic painDose-dependent fashionSerum estradiolOral gonadotropin-releasing hormone antagonistSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOverall pelvic painRates of amenorrheaDose-ranging trialRandomized clinical trialsNumber of respondersPrimary endpointBMD lossTotal hipFemoral neckHormone antagonistClinical centersParallel groupClinical trialsMineral densityLife measuresMAIN OUTCOMEEstrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Pluchino N, Mamillapalli R, Wenger JM, Ramyead L, Drakopoulos P, Tille JC, Taylor HS. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. Fertility And Sterility 2020, 113: 1224-1231.e1. PMID: 32416979, DOI: 10.1016/j.fertnstert.2020.01.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersConstipationCross-Sectional StudiesDysmenorrheaDyspareuniaEndometriosisEstrogen Receptor alphaFemaleHumansImmunohistochemistryMiddle AgedPain MeasurementPredictive Value of TestsProgestinsRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexTissue Array AnalysisTreatment OutcomeYoung AdultConceptsER-α expressionNumerical rating scaleProgesterone receptorAndrogen receptorDeep dyspareuniaDeep endometriosisImmunoreactive scoreProgestin therapyReceptor expressionTissue microarrayExpression of PRMultivariate logistic regression analysisER-α levelsSteroid receptor expressionTime of surgerySeverity of dysmenorrheaSeverity of symptomsLogistic regression analysisNonmenstrual painPain recurrencePain symptomsSevere dysmenorrheaPain persistencePain severityProgestin treatment
2019
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. American Journal Of Obstetrics And Gynecology 2019, 222: 592.e1-592.e10. PMID: 31759891, DOI: 10.1016/j.ajog.2019.11.1255.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painHealth-related qualityEndometriosis-associated painPelvic painMonth 3Clinical responseClinical respondersPain symptomsMeaningful improvementsEndometriosis-related pain symptomsSevere endometriosis-associated painSevere endometriosis-related painGonadotropin-releasing hormone antagonistPhase III clinical trialsPain reduction scoresPain responder statusSelf-reported bleedingPlacebo-controlled studyEndometriosis-related painSelf-reported painWork productivityReceiver-operating characteristic analysisNumber of symptomsProductivity QuestionnairePatterns of Prescription Opioid Use in Women With Endometriosis
Lamvu G, Soliman AM, Manthena SR, Gordon K, Knight J, Taylor HS. Patterns of Prescription Opioid Use in Women With Endometriosis. Obstetrics And Gynecology 2019, 133: 1120-1130. PMID: 31135725, PMCID: PMC6553518, DOI: 10.1097/aog.0000000000003267.Peer-Reviewed Original ResearchConceptsOpioid prescriptionsControl groupBenzodiazepine prescriptionsOpioid useEndometriosis patientsCase groupClinformatics DataMart databaseFirst opioid prescriptionMultiple opioid prescriptionsOpioid Prescribing PatternsPrescription opioid useMultivariable regression analysisRelative risk ratiosConcomitant opioidsPrescribing patternsDaily doseMean ageRisk ratioConcomitant useDays' supplyRetrospective analysisInsurance payerΧ statisticEndometriosisPatientsAndrogens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor
Usselman CW, Yarovinsky T, Steele FE, Leone CA, Taylor HS, Bender JR, Stachenfeld NS. Androgens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor. The Journal Of Physiology 2019, 597: 2853-2865. PMID: 30847930, DOI: 10.1113/jp277756.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrogensCardiovascular DiseasesDihydrotestosteroneEndothelin-1Endothelium, VascularEstrogensEthinyl EstradiolFemaleGlucose Tolerance TestHumansMicrovesselsNitric OxideObesityPolycystic Ovary SyndromeReceptor, Endothelin BSkinVascular Endothelial Growth Factor AVasodilationYoung AdultConceptsPolycystic ovary syndromeCardiovascular dysfunctionEndothelial dysfunctionOvary syndromeEndothelin-1Endothelial functionNO productionAndrogen receptor-dependent mannerEndothelin-B receptor subtypeCardiovascular risk factorsMicrovascular endothelial dysfunctionMicrovascular endothelial functionCutaneous vascular conductanceB receptor subtypesEndothelin B receptorLaser Doppler flowmetryNitric oxide inhibitionReceptor-dependent mannerEndothelial cell NO productionDose-response curveVasodilating responsePCOS subjectsLean womenObese womenVascular conductance
2018
Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis
Hu Z, Mamillapalli R, Taylor HS. Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis. AJP Endocrinology And Metabolism 2018, 316: e373-e382. PMID: 30576245, PMCID: PMC6459299, DOI: 10.1152/ajpendo.00244.2018.Peer-Reviewed Original ResearchConceptsEndometriotic cellsSteroidogenic factor 1Primary endometriotic cellsReproductive-aged womenAltered expressionSera of patientsPathogenesis of endometriosisCell proliferationFactor 1SF-1Novel therapeutic strategiesSteroidogenic acute regulatory proteinGynecologic diseaseEndometrial tissueEndometriotic lesionsAcute regulatory proteinSF-1 mRNA levelsEndometriosisTherapeutic strategiesEstrogen biosynthesisMRNA levelsRespective controlsWomenEssential transcriptional regulatorSerumProgesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis
Flores VA, Vanhie A, Dang T, Taylor HS. Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 4561-4568. PMID: 30357380, PMCID: PMC6226602, DOI: 10.1210/jc.2018-01227.Peer-Reviewed Original ResearchConceptsProgestin-based therapyPR statusReceptor statusEndometriotic lesionsPredictive valueEndometriosis-associated painProgesterone receptor levelsRetrospective cohort studyFirst-line treatmentProgesterone receptor statusNegative predictive valuePositive predictive valueElectronic medical recordsRabbit polyclonal IgGPrecision-based approachesProgestin therapyHormonal therapyEndometriosis treatmentCohort studyPredictive markerMedical recordsReceptor levelsH-scoreAcademic centersEndometriosisLong-Term Outcomes of Elagolix in Women With Endometriosis
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics And Gynecology 2018, 132: 147-160. PMID: 29889764, DOI: 10.1097/aog.0000000000002675.Peer-Reviewed Original ResearchConceptsMonths of treatmentResponder rateAdverse eventsPlacebo-controlled phase 3 trialGonadotropin-releasing hormone antagonistBone mineral density assessmentCoprimary efficacy endpointsEndometriosis-associated painNonmenstrual pelvic painPelvic pain scoresSafety of elagolixCommon adverse eventsPhase 3 trialProportion of respondersNew safety concernsBone mineral densityClinical laboratory testsElagolix dosesElagolix treatmentEndometrial findingsEfficacy endpointPain scoresPelvic painHot flushesTerm outcomesMajor depression, antidepressant use, and male and female fertility
Evans-Hoeker EA, Eisenberg E, Diamond MP, Legro RS, Alvero R, Coutifaris C, Casson PR, Christman GM, Hansen KR, Zhang H, Santoro N, Steiner AZ, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Ager J, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Lecks K, Martino L, Marunich R, Comfort A, Crow M, Hohmann A, Mallette S, Smith Y, Randolph J, Fisseha S, Ohl D, Ringbloom M, Tang J, Bates W, Mason S, Craig L, Zornes C, Rodriguez M, Hunt T, DiMaria N, Usadi R, Lucidi S, Rhea M, Baker V, Turner K, Brennan M, DelBasso D, Huang H, Jin Y, Li Y, Kuang H, Makuch R, Patrizio P, Sakai L, Scahill L, Song C, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Trussell J, Laylor B, Martinez L, Solnica A, Wojtczuk A, Seungdamrong A, Rosen M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Major depression, antidepressant use, and male and female fertility. Fertility And Sterility 2018, 109: 879-887. PMID: 29778387, PMCID: PMC5973807, DOI: 10.1016/j.fertnstert.2018.01.029.Peer-Reviewed Original ResearchConceptsMaternal major depressionMaternal antidepressant useAntidepressant useLikelihood of pregnancyMale partnersMajor depressionNon-IVF fertility treatmentsFirst trimester pregnancy lossTypes of antidepressantsPHQ-9 scoresFirst trimester miscarriagePatient Health QuestionnairePoor fertility outcomesRisk of miscarriagePoisson regression modelsPPCOS IICohort studyPregnancy outcomesMedication usePrimary outcomeRandomized trialsPregnancy lossHealth QuestionnaireRelative riskTreatment outcomesHematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis
Li F, Alderman MH, Tal A, Mamillapalli R, Coolidge A, Hufnagel D, Wang Z, Neisani E, Gidicsin S, Krikun G, Taylor HS. Hematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis. Stem Cells 2018, 36: 881-890. PMID: 29450941, PMCID: PMC5992028, DOI: 10.1002/stem.2804.Peer-Reviewed Original ResearchConceptsSerum CXCL12 levelsCXCL12 levelsEndometrial tissueEndometriosis lesionsHematogenous disseminationMesenchymal stem cell biomarkersCXCL12/CXCR4 axisStem cellsTreatment of endometriosisSham control miceEndometrial stem cellsHematopoietic stem cell markersStem cell biomarkersStem cell markersSpontaneous endometriosisRetrograde menstruationControl miceExperimental endometriosisRecipient miceCXCR4 axisLung tissueEndometriosisPeritoneal cavityDsRed miceBlood of animals
2017
Systemic Inflammation Induced by microRNAs: Endometriosis-Derived Alterations in Circulating microRNA 125b-5p and Let-7b-5p Regulate Macrophage Cytokine Production
Nematian SE, Mamillapalli R, Kadakia TS, Zolbin M, Moustafa S, Taylor HS. Systemic Inflammation Induced by microRNAs: Endometriosis-Derived Alterations in Circulating microRNA 125b-5p and Let-7b-5p Regulate Macrophage Cytokine Production. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 64-74. PMID: 29040578, DOI: 10.1210/jc.2017-01199.Peer-Reviewed Original ResearchConceptsSera of patientsMacrophage cytokine productionIL-1βIL-6Cytokine productionIL-8Let-7bIL-1β levelsCytokine protein levelsU937 macrophage cell lineCase-control studyTumor necrosis factorLet-7b inhibitorReal-time polymerase chain reactionEnzyme-linked immunosorbentQuantitative real-time polymerase chain reactionMessenger RNA changesSystemic inflammationAberrant inflammationInflammatory cytokinesProinflammatory cytokinesLevels of microRNAsUniversity HospitalPolymerase chain reactionMacrophage cell lineCigarette Smoking Affects Uterine Receptivity Markers
Ersoy G, Zhou Y, Inan H, Taner CE, Cosar E, Taylor HS. Cigarette Smoking Affects Uterine Receptivity Markers. Reproductive Sciences 2017, 24: 989-995. PMID: 28285568, DOI: 10.1177/1933719117697129.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cell lineCigarette smoking extractReceptivity markersImmunohistochemical analysisEndometrial stromal cell linePrimary human endometrial stromal cellsHuman endometrial stromal cellsFGF2 protein expressionUterine receptivity markersFGF2 expressionCigarette smoke exposureImpact of smokingEffect of smokingImpaired endometrial receptivityReal-time reverse transcription-polymerase chain reactionEndometrial stromal cellsC motif chemokine ligand 12Human endometrial samplesExpression of cytokinesReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionChemokine ligand 12FGF2 mRNA expressionMouse uterine tissueEndometrial healthTreatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply